Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Retailer Aeon Takes Controlling Position In Drug Store Chain CFS

This article was originally published in PharmAsia News

Executive Summary

Japan's major retailer Aeon will increase it shares in CFS Corp., a Shizuoka-based drug store chain. The companies agreed that Aeon will increase shares in CFS from 15 percent to 33.3 percent by acquiring a maximum of 28 million CFS shares in a friendly takeover bid. The companies also agreed to set up a team to implement the measures to strengthen branding and improve business. CFS President Kenji Ishida commented that the agreement will increase enterprise value and move the company toward achieving its business goal of total healthcare. Two Aeon executives will be appointed to the CFS board, and Aeon's Managing Director Tetsuo Imoto will become CFS's vice president. (Click here for more-J apanese language

You may also be interested in...

FDA Says GMP Lapses In Facilities And Production Areas More Common For Cell And Gene Therapies

US FDA investigators are more likely to cite cell and gene therapy manufacturers for facilities and production deficiencies, agency says, while industry reports difficulties complying with drug GMP requirements that are not always applicable to cell and gene therapies.

Anti-BCMA Therapies Aim To Raise The Bar In Myeloma

GSK’s antibody-drug conjugate may reach the market first, but CAR-T therapies from Bristol/bluebird and Janssen/Legend are close behind, and all three big pharmas have programs in earlier-stage disease.

The Quality Lowdown: US FDA Finding New Crop Of Data Integrity Problems

Manufacturers warned to keep better electronic records and not falsify data in recent warning letters, ICH adds three residual solvent limits for pharmaceuticals, and the Polish authority hits firm for GMP noncompliance.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts